Outlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
Outlook Therapeutics (NASDAQ:OTLK), a biopharmaceutical company developing bevacizumab treatments for retina diseases, announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. Bob Jahr, the company's newly appointed CEO, shared his professional journey and vision for the company's future in a video presentation.
The presentation is now accessible to investors through the Virtual Investor website and Outlook Therapeutics' investor relations page.
Outlook Therapeutics (NASDAQ:OTLK), una società biofarmaceutica che sviluppa trattamenti a base di bevacizumab per le malattie della retina, ha annunciato la sua partecipazione alla conferenza virtuale per investitori "What's Your Story" Summer Spotlight On-Demand. Bob Jahr, il nuovo CEO dell'azienda, ha condiviso il suo percorso professionale e la visione per il futuro della società in una presentazione video.
La presentazione è ora disponibile per gli investitori sul sito Virtual Investor e sulla pagina delle relazioni con gli investitori di Outlook Therapeutics.
Outlook Therapeutics (NASDAQ:OTLK), una compañía biofarmacéutica que desarrolla tratamientos con bevacizumab para enfermedades de la retina, anunció su participación en la conferencia virtual para inversores "What's Your Story" Summer Spotlight On-Demand. Bob Jahr, el recién nombrado CEO de la empresa, compartió su trayectoria profesional y visión para el futuro de la compañía en una presentación en video.
La presentación ya está disponible para los inversores a través del sitio web de Virtual Investor y la página de relaciones con inversores de Outlook Therapeutics.
Outlook Therapeutics (NASDAQ:OTLK)는 망막 질환 치료를 위한 베바시주맙 치료제를 개발하는 바이오제약 회사로, 가상 투자자 행사인 "What's Your Story" Summer Spotlight On-Demand 컨퍼런스에 참여했다고 발표했습니다. 회사의 신임 CEO인 Bob Jahr는 영상 발표를 통해 자신의 전문 경력과 회사의 미래 비전을 공유했습니다.
이 발표 영상은 현재 Virtual Investor 웹사이트와 Outlook Therapeutics 투자자 관계 페이지에서 투자자들이 시청할 수 있습니다.
Outlook Therapeutics (NASDAQ:OTLK), une société biopharmaceutique développant des traitements à base de bevacizumab pour les maladies de la rétine, a annoncé sa participation à la conférence virtuelle pour investisseurs "What's Your Story" Summer Spotlight On-Demand. Bob Jahr, le nouveau PDG de l'entreprise, a partagé son parcours professionnel ainsi que sa vision pour l'avenir de la société lors d'une présentation vidéo.
La présentation est désormais accessible aux investisseurs via le site Virtual Investor et la page des relations investisseurs d'Outlook Therapeutics.
Outlook Therapeutics (NASDAQ:OTLK), ein biopharmazeutisches Unternehmen, das Bevacizumab-Behandlungen für Netzhauterkrankungen entwickelt, gab seine Teilnahme an der virtuellen Investorenkonferenz "What's Your Story" Summer Spotlight On-Demand bekannt. Bob Jahr, der neu ernannte CEO des Unternehmens, teilte in einer Video-Präsentation seinen beruflichen Werdegang und seine Vision für die Zukunft des Unternehmens.
Die Präsentation ist nun für Investoren über die Virtual Investor Webseite und die Investor-Relations-Seite von Outlook Therapeutics zugänglich.
- None.
- None.
Video webcast now available on-demand
ISELIN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that Bob Jahr, newly appointed Chief Executive Officer, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference.
As part of the event, Mr. Jahr dove deeper into what brought him to Outlook Therapeutics, how he got to where he is today and provided insight into why he is excited about the future for Outlook Therapeutics.
The on-demand video webcast is now available on virtualinvestorco.com as well as the Events page under the Investors section of the Company’s website (outlooktherapeutics.com).
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD.
In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational, and a BLA has been resubmitted to the FDA. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com
FAQ
When did Outlook Therapeutics (OTLK) participate in the Virtual Investor Summer Spotlight Conference?
Who is the new CEO of Outlook Therapeutics (OTLK)?
Where can investors watch Outlook Therapeutics' (OTLK) Virtual Investor Conference presentation?
What is Outlook Therapeutics' (OTLK) main business focus?
